MM
Michael Marks
@drmichaelmarks.bsky.social
Professor of Medicine at LSHTM.
Lead for Integrated Academic Training at LSHTM.
Consultant in Infectious Diseases at UCLH.
Syphilis & STIs, Neglected Tropical Diseases, Emerging Infectious Diseases, Group A Strep, Pragmatic Trials
72 followers78 following6 posts
Different trials for each. There is a fairly worked up proposal for a "definitive treatment trial" but that can't easily get at Q's on empiric IVIG & anti-toxins. The latter much harder as syndromes caused by a range of bacteria some where interventions might help and some where we presume does zero
Fair enough, but presumably more efficient to nest the IVIG/anti-toxin randomisation within an existing definitive treatment trial?
MM
Michael Marks
@drmichaelmarks.bsky.social
Professor of Medicine at LSHTM.
Lead for Integrated Academic Training at LSHTM.
Consultant in Infectious Diseases at UCLH.
Syphilis & STIs, Neglected Tropical Diseases, Emerging Infectious Diseases, Group A Strep, Pragmatic Trials
72 followers78 following6 posts